involved and, to a much lesser extent, in uninvolved skin of patients with atopic dermatitis, but not on LC from nonatopic individuals (1, 2). This finding indicated that, in atopic dermatitis, LC are induced to either synthesize receptors for IgE and/or to acquire IgE-binding FceR2 split products. As opposed to the selective expression of FcER1 by basophils and mast cells, low affinity Fc-IgE receptors (FceR2/CD23) have been described on numerous cell types including B and T cells, eosinophils, platelets, and monocytes (3, 4). The most recent finding that an anti-FceR2 mAb can inhibit the binding of IgE-coated ox erythrocytes to LC from atopic dermatitis patients (5) supports the contention that the presence of IgE on LC surfaces in this disease results from the binding of IgE to FceR2 . For many of the above cells, FceR2/CD23 expression is not a constitutive event but rather regulated by soluble mediators including human rIL-4 (hrIL-4 ; 6, 7), human rIFN-y (hrIFN -y; 6, 8), and PMA (8).
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BRIEF DEFINITIVE REPORT Marseille, France) were used for control purposes. The IgE myeloma protein sha was purified by DEAE chromatography and used at a concentration of 10 Fcg/ml . FITC-labeled goat anti-mouse (GAM/FITC) was obtained from Grub Laboratories, Scandic, Vienna, Austria. FITC-labeled goat anti-human IgE (GAHuIgE/FITC) was purchased from Dakopatts, Hamburg, FRG. LC-enriched Human Epidermal Cells. Cells were prepared as described elsewhere (Yokozeki, H., A. Rieger, C. Forster, A. Binder, V. Groh, and G. Stingl, submitted for publication) . Briefly, split-thickness specimens of cadaver skin were subjected to 0.5% trypsin/PBS for 90 min at 37'C . The loosened epidermis was then peeled off and vigorously agitated in FCS (Gibco Laboratories, Berlin, FRG)-supplemented RPMI 1640 containing 0.01% DNase (Sigma Chemical Co., St. Louis, MO) . After several washes, resulting single cell suspensions were incubated on collagen-coated petri dishes, which resulted in a preferential attachment ofbasal keratinocytes. Based on our previous observation that differentiating keratinocytes are more susceptible to osmotic shock treatment than other epidermal cells, nonadherent cells were then collected by vigorous pipetting and subjected to hypotonic PBS/Aqua destillata mixture for 1 min under mechanical agitation . Resulting cells (viability -20%) were freed ofdead cells by FicollHypaque density gradient centrifugation ; interface cells recovered (viability >95% by trypan blue exclusion) were collected and the quality of LC-enrichment was controlled by FITC-OKT6. The possibility that other hematopoietic cells were substantially coenriched for by this negative selection procedure can be excluded by our previous finding that >-98% of CD45`cells in the final cell preparation coexpressed CDla antigens (Yokozeki, H., et al., submitted).
The FceR2/CD23' Human Monoblastic Cell Line U937 The U937 cell line was donated by H. L. Spiegelberg (Dept. ofImmunology, Scripps Clinic and Research Foundation, LaJolla, CA) . This cell line reacts with M-L25 and 3-5 (Bieber, T., unpublished data).
Cell Cultures . 105 LC-enriched epidermal cells cultured for 8-48 h either in U-shaped bottom 96-well microtiter plates or in 24-well plates (106/ml) in RPMI 1640 (Flow Laboratories, Meckenheim, FRG) containing 10% FCS (Gibco Laboratories), 1% antibiotics/antimycotics (Gibco), 2 MM L-glutamine (Gibco), 25 mM Hepes buffer (Seromed, Berlin, FRG), 5 mM sodium-pyruvate (Gibco), and 1% nonessential amino acids (Gibco) .
U937 cells were grown in RPMI 1640 supplemented with 10% FCS, 1% antibiotics/antimycotics, and 2 MM L-glutamine (all from Gibco Laboratories) .
For the FceR2/CD23 induction assay, cells were cultured in either absence or the presence ofone orseveral ofthe following substances: hrIL-2, hrIL-4, 1-1,000 IU/ml (Genzyme Corp., Boston, MA) ; hrIFN--y, 1-1,000 IU/ml (Bender, Vienna, Austria); 2 ng/ml PMA (Sigma Chemical Co) ; and 5 LM/ml cycloheximide (Sigma) . As negative control experiments, the cells were cultured in medium without exogenous cytokines.
LC Immunolabeling by Double-Marker Analysis . LC-enriched epidermal cells were first stained with T6/RDl, then washed and reacted with ox eythrocytes coated with either M-L25 or 3-5, or as a control, with BIP-1 as described previously (13) . Finally, the cells were resuspended and analyzed for viability, surface staining, and rosette formation using a Leitz Aristoplan fluorescence microscope. To verify the specificity of the rosette formation, an inhibition study was carried out by incubation of the epidermal cell cultures with unlabeled M-L25 or 3-5 (20 tzg/ml) or isotype control at 4'C for 30 min. The cells were then washed twice in supplemented RPMI 1640 and incubated with anti-CD23 mAb-coated erythrocytes as described above.
Determination of IgE Binding andFceR2/CD23 Expression on Cultured Cells. After being cultured in the presence of cytokines, LC-enriched epidermal cells (5 x 105/ml) or U937 cells (5 x 105/ ml) were washed twice in supplemented RPMI 1640 and were then incubated for 30 min with heat-inactivated AB serum . A small aliquot of this cell suspension was used to monitor by immunofluorescence CD23 expression by LC using M-L25 (20 hg/ml) and GAM/FITC in a consecutive order. A larger portion of the cultured cells was incubated with 10 Wg/ml myeloma IgE for 45 min on ice, washed twice in PBS supplemented with 1% FCS and 0.1% sodium azide at 4°C and then incubated with GAHuIgE/FITC (10 jig/ml) for 45 min on ice . Controls included the use of GAHuIgE/FITC alone as well as F(ab')2 fragments of GAHuIgM/ FITC and GAHuIgG/FITC (all obtained from Immunotech), respectively. In other experi- Induction ofAnti-FccR2/CD23 Reactivity ofLC by hrIL-4 and hrIFN-y. While LCenriched epidermal cells either freshly isolated or cultured in media alone did not react with anti-CD23 reagents by either immunofluorescence or rosetting, hrIL-4 as well as hrIFN-,y led to a gradual, dose-dependent emergence of anti-CD23-reactive cells. Double-marker analysis revealed that CD23 expression was confined to the CDla' cells, i.e., to LC. Reactivity of LC with M-L25-coated ox erythrocytes occurred in a dose-dependent fashion, whereas 10 U/ml of each cytokine resulted in anti-CD23 reactivity of only 3 ± 1% (hrIL-4) and 2 ± 2% (hrIFN-'y) ofLC, respectively, 1,000 U/ml ofhrIL-4 and hrIFN-y led to a specific anti-CD23 immunolabeling of 15 ± 7 and 8 ± 3 % of LC, respectively (Table I) . Similar results were obtained with 3-5-coated erythrocytes under the same conditions. A combined use of varying hrIL-4/hrIFN-y concentrations showed that, at each combination chosen, these cytokines act synergistically on CD23 expression by LC (Table I) but only in an additive fashion on that of U937 cells (data not shown); maximal CD23 induction on LC was regularly seen with 1,000 U/ml ofboth cytokines . In this context, it should be noted that the cytokine concentrations needed for the induction of CD23 antigen on LC are either within the same range or only slightly higher than those needed for CD23 induction of B cells and U937 cells, respectively (6, 14) . Kinetic studies revealed that, when using each cytokine (1,000 U/ml) either alone or in combina- tion, substantial CD23 expression by LC was first detectable after 16 h and peaked after 24 h. Time course studies beyond this point were hardly feasible because of the rapidly declining viability of the cells (<20% after 48 h of culture) . Our further observation that the addition of cycloheximide to the cultures entirely abrogated the inductive capacities of the cytokines used either alone or in combination, shows that the cytokine-induced CD23 expression on LC is due to the synthesis of this antigen rather than due to unhiding of preformed moieties . As opposed to hrIL-4 and hrIFN-y, hrIL-2 (100 and 200 U/ml) and PMA failed to induce CD23 antigens on any epidermal cell. Comparative studies with U937 cells which are known to constitutively exhibit FceR2/CD23 revealed a mean baseline expression of CD23 expression on 17 t 4% of the cells and an increase of the expression after 24 h of culture with either hrIL-4 (58 ± 10%) or hrIFN-y (49 ± 8%). While IL-2 was again ineffective in CD23 induction, PMA, in contrast to LC, greatly upregulated CD23 expression (90 ± 5°Io of cells) .
FceR2/CD23+ LC Bind IgE Molecules . To see if the FceR2/CD23+ LC were able to bind IgE molecules, LC-enriched epidermal cells that had been stimulated with 1,000 U/ml of both hrIL-4 and hrIFN-y were successively incubated with myeloma IgE and anti-IgE/FITC and then analyzed by flow cytometry. These experiments revealed a positive staining of 23 ± 4°/ of the LC (Fig. 1) . This percentage was less than that obtained by flow cytometry with the anti-CD23 reagent (40 ± 6%) and probably due to the low affinity of the receptor. When preincubation with M-L25 was followed by myeloma IgE, no IgE binding could be demonstrated on cultured LC-enriched epidermal cells or U937 cells.
Discussion
In this study, we have shown that (a) freshly isolated human epidermal cell from nonatopic donors greatly enriched for CDla+ LC fail to react with anti-CD23 mAb as assessed by indirect immunofluorescence and rosette assays, respectively ; (b) a percentage of the LC exhibit anti-FceR2/CD23 reactivity when cultured for 24 h in the presence of hrIL-4 and/or hrIFN-y, but not when cultured in the presence of hrIL-2, PMA, or culture medium alone, and that this hrIL-4/hrIFN-y-induced emergence of anti-FceR2/CD23 immunolabeling ofLC can be prevented by adding cycloheximide to the culture media; (c) a considerable percentage of LC when cul-tured in the presence of hrIL-4/hrIFN--y , but not when cultured in media alone, bind IgE molecules and that this binding can be prevented by preincubation of the cells with anti-FcER2/CD23 mAb.
The key observation made in this study, i .e ., the triggering of anti-FceR2/CD23 moieties on LC by hrIL-4/hrIFN-y, can be either explained by the induction of biosynthesis of these structures, or alternatively, by the unmasking or exocytosis of preformed proteins . The prevention of the cytokine-induced appearance of anti-FceR2/CD23-reactive LC by cycloheximide proved the validity of the former assumption . Epidermal cell suspensions used in our study were greatly enriched for LC, but still contained a large number of keratinocytes, a putative source of cytokines (15) . The cytokine-driven synthesis of anti-FceR2/CD23-reactive structures by LC may therefore either be due to a direct effect of hrIL-4/rhIFN-y on LC, or alternatively, due to keratinocyte activation by these cytokines leading to the production/release of other mediators responsible for the observed phenomenon .
In many cell types investigated, pronounced differences exist between hrIL-4 and hrIFN-y in their capacity to modulate FceR2/CD23 expression (6) (7) (8) .
One of the few cell types exhibiting reaction patterns to these cytokines similar to LC, i .e., upregulation Although data presented in this study suggest that secretory products of either circulating or infiltrating T cells are responsible for the in vivo induction of FceR2 in atopic dermatitis patients, the possibility still exists that functional alterations of resident skin cells contribute to the occurrence of this event . In this context it should be noted that anti-IgE+ LC have not been detected in noneczematous atopic patients (1, 2) . This may indicate that the presence of FceR2-bound IgE molecules on LC surfaces in atopic dermatitis patients is not simply a functionally irrelevant bystander phenomenon of atopy itself but is rather involved in the pathogenesis of the eczematous process .
The experimental model presented in this study will allow us to investigate the molecular aspects of native IgE or IgE-antigen complexes binding to LC-FceR2, as well as the effects of this interaction on the function of this cell type .
Summary
Human rIL-4 and human rIFN-y are able to induce the expression of the low affinity receptor for IgE (FceR2/CD23) on normal human epidermal Langerhans cells, whereas IL-2 and PMA have no effect . A synergistic effect is observed when both cytokines are combined . These receptors are synthesized de novo by the LC since cycloheximide completely inhibits the appearance of FceR2/CD23 . FceR2/CD23 + LC may have a major role in the pathogenesis of atopic eczema, as well as in the regulation of IgE synthesis .
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